Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy

Flavia Longo, Giovanni Mansueto, Vittoria Lapadula, Rita De Sanctis, Silvia Quadrini, Roberta Grande, Bruno Gori, Amelia Altavilla, I. D'Antoni, Ester Del Signore, Luciano Stumbo, Cristina De Luca, Barbara Cimadon, Enrico Cortesi, Teresa Gamucci, Marisa Di Seri

Research output: Contribution to journalArticle

Abstract

Background: The combination of a neurokinin-1 receptor antagonist, dexamethasone, and a 5-HT 3 receptor antagonist is currently the standard antiemetic treatment in patients receiving cisplatin-based high emetogenic chemotherapy (HEC). The aim of this study was to evaluate the efficacy of a combination of palonosetron, a unique second-generation 5-HT 3 receptor antagonist, aprepitant, the only approved neurokinin-1 receptor antagonist, and dexamethasone as antiemetic prophylaxis in patients receiving HEC (cisplatin ≥50 mg/mq). Methods: Chemotherapy-naïve adult patients, receiving cisplatin-based HEC, were treated with palonosetron 0.25 mg/i.v., dexamethasone 20 mg/i.v., and aprepitant 125 mg/p.o., 1-h before chemotherapy. Aprepitant 80 mg/p.o. and dexamethasone 4 mg p.o. were administered on days 2-3. Primary end point was complete response (CR; no vomiting and no use of rescue medication), during the overall study period (0-120 h). Secondary end points were complete control (CR and no more than mild nausea), emesis-free rate, and nausea-free rate during the acute (0-24 h), delayed (24-120 h), and overall (0-120 h) periods. Safety was also evaluated. Results: A total of 222 patients were included in the study. Median age was 62 years, 76.6% were male and 23.4% female, and most common tumors were lung (66.7%) and head and neck (15.8%); 70.3% of patients achieved CR during the overall study period. Complete control, emesis-free rate, and nausea-free rate were 70.3%, 92.8%, and 59.9%, respectively, during the overall phase. The most commonly reported side effects were constipation (39% of patients) and headache (5%). Conclusions: This study shows that palonosetron in combination with aprepitant and dexamethasone is effective to prevent chemotherapy-induced nausea and vomiting in patients treated with cisplatin-based HEC.

Original languageEnglish
Pages (from-to)1159-1164
Number of pages6
JournalSupportive Care in Cancer
Volume19
Issue number8
DOIs
Publication statusPublished - Aug 2011

Keywords

  • 5-HT receptor antagonist
  • Aprepitant
  • CINV
  • Dexamethasone
  • HEC
  • Palonosetron

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy'. Together they form a unique fingerprint.

  • Cite this

    Longo, F., Mansueto, G., Lapadula, V., De Sanctis, R., Quadrini, S., Grande, R., Gori, B., Altavilla, A., D'Antoni, I., Del Signore, E., Stumbo, L., De Luca, C., Cimadon, B., Cortesi, E., Gamucci, T., & Di Seri, M. (2011). Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy. Supportive Care in Cancer, 19(8), 1159-1164. https://doi.org/10.1007/s00520-010-0930-x